NEW YORK (GenomeWeb News) – NextBio today announced it has forged a multiyear deal with Sanofi for use of the NextBio Clinical platform in the drug manufacturer's R&D work.

Sanofi will use the platform for aggregating, standardizing, and analyzing patient clinical data, next generation sequencing, and other molecular data across public data sources, Sanofi's clinical trials, and Sanofi's hospital partners, NextBio said. Sanofi is using the NextBio Clinical platform as part of its Translational Medicine for Patients program.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: caution urged in use of gene drives, and more.

NIH's Sally Rockey examines the tapped and untapped potential of the NIH peer reviewer pool.

PLOS Biology has asked researchers how they envision the future of genetics and genomics.

Representative Lamar Smith brings back a provision to require the National Science Foundation to certify that each study it funds is "in the national interest."